SEATTLE — In this Healio Video Perspective from the ASRS annual meeting, Tarek S. Hassan, MD, discusses a novel treatment paradigm under investigation for geographic atrophy and dry age-related macular degeneration.
“We are looking to harness nature’s own immune system and the way that that is regulated to ultimately drive it in the way that we want it to,” he said.
Hassan said AVD-104 (Aviceda Therapeutics), a sialic acid-coated nanoparticle, may be able to “turn off” macrophages and microglia, the effector cells that cause geographic atrophy, when delivered